Donna Berry on Winning Researcher Award

May 7, 2011

Donna L. Berry, PhD, RN

Donna Berry on the Distinguished Researcher Award and Her Advice to Researchers

Donna Berry, PhD, RN, AOCN®, FAAN, Phyllis F. Cantor Center, Dana-Farber Cancer Institute, Boston, MA describes her feelings on winning the 2011 ONS Distinguished Researcher Award and shares her advice for other oncology nurse researchers who are just starting their careers.

View more videos of Donna Berry, PhD, RN.

Related Videos

Sohail Dhanji, MD

Eric A. Singer, MD

Sia Daneshmand MD

Fred Saad, MD, FRCS

Benjamin H. Lowentritt, MD, FACS

Roger Li, MD

Michael Basin, MD

Andrew Katims, MD, MPH

Jason J. Luke, MD, FACP, of UPMC Hillman Cancer Center

Ferdinandos Skoulidis, MD, PhD, MRCP

Related Content

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

Sacituzumab Govitecan Elicits Consistent Safety in Patients With HR+/HER2– Breast Cancer, Regardless of UGT1A1 Status

Atezolizumab Plus Trastuzumab/Vinorelbine Elicits Responses in HER2+ Advanced Breast Cancer

Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities

Telephone-Based Weight Loss Program Is Effective for Breast Cancer Survivors

Pembrolizumab Plus Chemo With or Without Bevacizumab Maintains OS Benefit in Frontline Cervical Cancer

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

Sacituzumab Govitecan Elicits Consistent Safety in Patients With HR+/HER2– Breast Cancer, Regardless of UGT1A1 Status

Atezolizumab Plus Trastuzumab/Vinorelbine Elicits Responses in HER2+ Advanced Breast Cancer

Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities

Telephone-Based Weight Loss Program Is Effective for Breast Cancer Survivors

Pembrolizumab Plus Chemo With or Without Bevacizumab Maintains OS Benefit in Frontline Cervical Cancer

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

Sacituzumab Govitecan Elicits Consistent Safety in Patients With HR+/HER2– Breast Cancer, Regardless of UGT1A1 Status

Atezolizumab Plus Trastuzumab/Vinorelbine Elicits Responses in HER2+ Advanced Breast Cancer

Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities

Telephone-Based Weight Loss Program Is Effective for Breast Cancer Survivors

Pembrolizumab Plus Chemo With or Without Bevacizumab Maintains OS Benefit in Frontline Cervical Cancer

Related Content

Jane Meisel, MD

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

Frederik Marmé, MD, PhD,

Sacituzumab Govitecan Elicits Consistent Safety in Patients With HR+/HER2– Breast Cancer, Regardless of UGT1A1 Status

Eva Ciruelos Gil, MD, PhD

Atezolizumab Plus Trastuzumab/Vinorelbine Elicits Responses in HER2+ Advanced Breast Cancer

Julie R. Gralow, MD, FACP, FASCO

Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities

Dr Jennifer Ligibel

Telephone-Based Weight Loss Program Is Effective for Breast Cancer Survivors

Bradley J. Monk, MD, FACS, FACOG

Pembrolizumab Plus Chemo With or Without Bevacizumab Maintains OS Benefit in Frontline Cervical Cancer

Latest Conference Coverage

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

Sacituzumab Govitecan Elicits Consistent Safety in Patients With HR+/HER2– Breast Cancer, Regardless of UGT1A1 Status

Atezolizumab Plus Trastuzumab/Vinorelbine Elicits Responses in HER2+ Advanced Breast Cancer

Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.